Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Brotchie

Showing results (31-40 of 127) with videos related to

Pageof 13
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|July 26, 2011
Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?Philippe Huot, Susan H Fox, Adrian Newman-Tancredi, et al.
Synapse (New York, N.Y.)|January 7, 2015
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot studyPhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2007
Levodopa-induced dyskinesiasGiovanni Fabbrini, Jonathan M Brotchie, Francisco Grandas, et al.
Plos One|December 1, 2016
Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in MacaqueJames B Koprich, Tom H Johnston, Gabriela Reyes, et al.
Synapse (New York, N.Y.)|February 5, 2008
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's diseaseJoohyung Lee, Jordi Gomez-Ramirez, Tom H Johnston, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2010
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's diseaseTom H Johnston, Anne van der Meij, Jonathan M Brotchie, et al.
Neurobiology of Aging|June 22, 2010
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPAPhilippe Huot, Tom H Johnston, Lieke Winkelmolen, et al.
Experimental Neurology|October 14, 2003
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's diseaseBrian Henry, Susan Duty, Susan H Fox, et al.
NPJ Parkinson'S Disease|December 10, 2020
Exosome markers of LRRK2 kinase inhibitionShijie Wang, Kaela Kelly, Jonathan M Brotchie, et al.
Annals of Neurology|October 7, 2017
Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"James B Koprich, Jonathan M Brotchie, Thomas Musacchio, et al.
Pageof 13

Showing results (31-40 of 127) with videos related to

Sort By:
Pageof 13
The Journal of Pharmacology and Experimental Therapeutics|July 26, 2011
Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?Philippe Huot, Susan H Fox, Adrian Newman-Tancredi, et al.
Synapse (New York, N.Y.)|January 7, 2015
Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot studyPhilippe Huot, Tom H Johnston, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 13, 2007
Levodopa-induced dyskinesiasGiovanni Fabbrini, Jonathan M Brotchie, Francisco Grandas, et al.
Plos One|December 1, 2016
Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in MacaqueJames B Koprich, Tom H Johnston, Gabriela Reyes, et al.
Synapse (New York, N.Y.)|February 5, 2008
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's diseaseJoohyung Lee, Jordi Gomez-Ramirez, Tom H Johnston, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2010
Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's diseaseTom H Johnston, Anne van der Meij, Jonathan M Brotchie, et al.
Neurobiology of Aging|June 22, 2010
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPAPhilippe Huot, Tom H Johnston, Lieke Winkelmolen, et al.
Experimental Neurology|October 14, 2003
Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's diseaseBrian Henry, Susan Duty, Susan H Fox, et al.
NPJ Parkinson'S Disease|December 10, 2020
Exosome markers of LRRK2 kinase inhibitionShijie Wang, Kaela Kelly, Jonathan M Brotchie, et al.
Annals of Neurology|October 7, 2017
Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"James B Koprich, Jonathan M Brotchie, Thomas Musacchio, et al.
Pageof 13